Regulation - Anti-virals, Vertex

Filter

Current filters:

Anti-viralsVertex

Popular Filters

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco

20-12-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

Vertex plans for Kalydeco launch

09-01-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) announced its 2012 business objectives in conjunction…

Anti-viralsIncivekKalydecoPharmaceuticalRare diseasesRegulationResearchVertex

Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C

21-09-2011

The European Commission has approved Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Incivo (telaprevir),…

Anti-viralsEuropeIncivekIncivoJanssen PharmaceuticaJohnson & JohnsonPharmaceuticalRegulationtelaprivirVertex

Regulatory updates for Incivek, Xgeva and Corlux in North America

23-08-2011

In a batch of regulatory news released yesterday, Vertex Pharmaceuticals (Nasdaq: VRTX) said that Health…

AmgenAnti-viralsCorcept TherapeuticsCorluxIncivekNorth AmericaPharmaceuticalRare diseasesRegulationVertexXgeva

Back to top